...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Open Forum Infectious Diseases >Comparison of Adverse Drug Reactions Between Patients Treated With Ceftaroline or Ceftriaxone: A Single-Center, Matched Cohort Study
【24h】

Comparison of Adverse Drug Reactions Between Patients Treated With Ceftaroline or Ceftriaxone: A Single-Center, Matched Cohort Study

机译：头孢洛林或头孢曲松钠治疗患者之间药物不良反应的比较：单中心配对队列研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundLittle information is available on the relative tolerability of ceftaroline versus other cephalosporins in clinical practice. We sought to compare adverse drug reactions (ADRs) associated with ceftaroline with those associated with ceftriaxone in hospitalized patients.Materials and MethodsThis was a retrospective, single-center matched cohort (according to age, indication, and duration) study of patients treated with ceftaroline or ceftriaxone at the VA St Louis Health Care System between 29 October 2010 and 28 March 2017, to compare rates of ADRs between the agents. Patients included received ≥2 doses of either medication to treat osteomyelitis, acute bacterial skin and skin structure infection, blood stream infection, pneumonia, infective endocarditis, septic arthritis, prosthetic joint infection, or empyema. The primary and secondary outcomes were the composite of any ADR during therapy and any ADR leading to premature discontinuation of therapy. The ADRs evaluated included rash, neutropenia, acute kidney injury, eosinophilia, thrombocytopenia, transaminitis, and hyperbilirubinemia.ResultsAfter matching, 50 patients per group were included and analyzed. An ADR occurred in 20% (10 of 50) of patients treated with ceftriaxone and 16% (8 of 50) of those treated with ceftaroline (P = .60). Two percent (1 of 50) of those treated with ceftriaxone and 16% (8 of 50) treated with ceftaroline had therapy discontinued owing to an ADR (P = .03). The most common ADR was eosinophilia (3 of 50) in the ceftriaxone group and rash (5 of 50) in the ceftaroline group. Ceftaroline therapy was identified as an independent risk factor for an ADR requiring premature discontinuation (odds ratio, 10.2; 95% confidence interval, 1.19–87.8; P = .03).ConclusionsAlthough there was no difference in the rates of ADRs between patients in the ceftriaxone and ceftaroline groups, significantly more ceftaroline-treated patients required premature discontinuation.
机译：背景在临床实践中，关于头孢洛林与其他头孢菌素的相对耐受性的信息很少。我们试图比较住院患者中与头孢洛林相关的不良药物反应（ADR）与与头孢曲松相关的药物不良反应（ADR）。于2010年10月29日至2017年3月28日之间在VA St Louis卫生保健系统中使用头孢曲松或头孢曲松钠进行比较，以比较各代理商之间的ADR发生率。接受治疗的患者接受≥2剂两种药物治疗骨髓炎，急性细菌性皮肤和皮肤结构感染，血流感染，肺炎，感染性心内膜炎，化脓性关节炎，假体关节感染或脓胸。主要和次要结果是治疗期间任何ADR以及导致治疗提前终止的任何ADR的综合结果。评估的ADR包括皮疹，中性粒细胞减少，急性肾损伤，嗜酸性粒细胞增多症，血小板减少症，转氨性炎和高胆红素血症。结果匹配后，每组包括50例患者并进行分析。头孢曲松治疗的患者中有20％（50名患者中有10名）发生了不良反应，而头孢太林治疗的患者中有16％（50名中有8名）发生了ADR（P = 0.60）。接受头孢曲松治疗的患者中有2％（50名患者中的1名）和使用头孢洛林治疗的患者中有16％（50名患者中的8名）由于ADR而终止治疗（P = .03）。头孢曲松组最常见的ADR是嗜酸性粒细胞增多（50中的3），而头孢太林组中的皮疹（50中的5）。头孢洛林治疗被确定为需要提前终止ADR的独立危险因素（赔率，10.2; 95％置信区间，1.19-87.8; P = .03）。头孢曲松组和头孢洛林组中，头孢洛林治疗的患者明显需要过早停药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号